Skip to Content

Anthera Pharmaceuticals Inc ANTH

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ANTH is trading at a 60% discount.
Price
$0.00
Fair Value
$6.47
Uncertainty
Extreme
1-Star Price
$9.86
5-Star Price
Economic Moat
Dmzn
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ANTH is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.01
Bid/Ask
$0.00 / $0.02
Market Cap
$26.18
Volume/Avg
387 / 16,806

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
21

Valuation

Metric
ANTH
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ANTH
Quick Ratio
3.06
Current Ratio
3.30
Interest Coverage
Quick Ratio
ANTH

Profitability

Metric
ANTH
Return on Assets (Normalized)
−232.18%
Return on Equity (Normalized)
−2,188.44%
Return on Invested Capital (Normalized)
−1,887.01%
Return on Assets
ANTH
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRKnsx$550.2 Bil
VRTX
Vertex Pharmaceuticals IncMkrvkl$111.1 Bil
REGN
Regeneron Pharmaceuticals IncYjtqcz$107.7 Bil
MRNA
Moderna IncWmc$36.9 Bil
ARGX
argenx SE ADRWfbrf$24.2 Bil
BNTX
BioNTech SE ADRMmn$22.3 Bil
ALNY
Alnylam Pharmaceuticals IncYvpggw$19.9 Bil
BMRN
Biomarin Pharmaceutical IncKtjvzd$17.2 Bil
RPRX
Royalty Pharma PLC Class AWmsvrv$13.9 Bil
INCY
Incyte CorpKhghbhj$13.6 Bil

Sponsor Center